What is Royalty Pharma's phase 2b, tev-408 — research and development commitment?

Royalty Pharma (RPRX) reported phase 2b, tev-408 — research and development commitment of $75.00M in Q1 2026.

Products & Services · Research and development commitment

Phase 2b, TEV-408 — Research and development commitment

Analysis

StatementSegment

CategoryCapital Allocation

SignalContext dependent

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

How to read this metric

An increase indicates a higher strategic priority and increased investment in the asset's development, while a decrease may signal a reduction in scope, project completion, or a shift in capital allocation strategy.

Detailed definition

This metric represents the total contractual or planned financial obligation allocated to the research and development o...

Peer comparison

Comparable to R&D budget allocations or committed milestone payments for specific clinical-stage assets at other biopharmaceutical or royalty-focused firms.

Metric ID: rprx_segment_phase_2b_tev_408_research_and_development_commitment

Historical Data

1 periods

	Q1 '26
Value	$75.00M

Similar Metrics at Other Companies

Roivant SciencesROIV View metric

United TherapeuticsUTHR View metric

Eli LillyLLY View metric

Roivant SciencesROIV View metric

Eli LillyLLY View metric

Frequently Asked Questions

What is Royalty Pharma's phase 2b, tev-408 — research and development commitment?: Royalty Pharma (RPRX) reported phase 2b, tev-408 — research and development commitment of $75.00M in Q1 2026.
What does phase 2b, tev-408 — research and development commitment mean?: The total amount of capital the company has committed to spend on the Phase 2b clinical development of the TEV-408 drug candidate.